Clear-cell cancer of the ovary?is it chemosensitive?
- 1 May 2005
- journal article
- Published by BMJ in International Journal of Gynecologic Cancer
- Vol. 15 (3), 432-437
- https://doi.org/10.1111/j.1525-1438.2005.15305.x
Abstract
The records of all patients with clear-cell ovarian cancer (CCC) who underwent complete surgical staging and chemotherapy between 1984 and 2001 were reviewed and 39 patients identified as suitable for study. The mean patient age was 56 years, and the stage distribution was as follows: stage I, 53%; stage II, 13%; stage III, 32%; and stage IV, 2%. One in three patients with stage I disease developed recurrent disease despite adjuvant chemotherapy. Seventy percent of tumors demonstrated a response to combination carboplatin and paclitaxel. Tumors which had either a partial response or failed to respond to first-line chemotherapy demonstrated no response to second-line nonplatinum chemotherapy. Endometriosis was identified in 31% of tumors, and 18% of patients developed deep venous thrombosis (DVT); however, neither endometriosis nor DVT was associated with a poorer outcome. CCC has a high recurrence rate in early-stage disease despite adjuvant treatment with cytotoxic chemotherapy. Advanced disease does respond to carboplatin and paclitaxel, which should be the chemotherapeutic regimen of choice. New second-line agents are urgently required.Keywords
This publication has 22 references indexed in Scilit:
- Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovaryObstetrics & Gynecology, 2002
- Clinical characteristics of clear cell carcinoma of the ovaryCancer, 2000
- Clinical Characteristics of Clear Cell Carcinoma of the OvaryGynecologic Oncology, 1998
- Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapyCancer, 1996
- Clear Cell Carcinoma of the Ovary: A Distinct Histologic Type with Poor Prognosis and Resistance to Platinum-Based Chemotherapy in Stage III DiseaseGynecologic Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Establishment and Characterization of Two Human Ovarian Clear Cell Adenocarcinoma Lines from Metastatic Lesions with Different PropertiesGynecologic Oncology, 1995
- Clear Cell Epithelial Ovarian Cancer (Mesonephroid): Bad Prognosis Only in Early StagesGynecologic Oncology, 1993
- Ovarian clear cell adenocarcinomaGynecologic Oncology, 1989
- Clear cell adenocarcinoma of the ovary: A clinical analysis and comparison with serous carcinomaGynecologic Oncology, 1989